Introducing MOAT - the BIOIO platform
MOAT (mechanism of action technologies) is a MoA-driven clinical indication prediction engine. MOAT combines both experimental and computational approaches.
All -omic approaches aren’t created equal
We deploy multi-omics, but based on two decades of experience, cell fitness based, unbiased genome-wide screening is the gold standard for establishing a small molecule’s MoA. Cell fitness (i.e., cell counting) is the only -omic phenotype that creates faithful signal to noise amplification. It’s the key differentiator from all other -omic techniques, be they genetic or biochemical. Importantly, the 2nd generation of the MOAT platform, MOAT 2.0, is now capable of performing the genomic screens virtually. These AI-generated predictions are highly accurate, thereby eliminating considerable time and cost in doing experiments.
The strengths of our approach are two-fold
First, ensuring an accurate understanding of a small molecule’s MoA is vital to establishing contexts in which it might be effective and what its side effect liabilities might be. For example, in cancer, therapies are often used in combinations. Being precise about what each therapy uniquely targets is what enables strong synergies. The second strength of our MoA-led approach is that we ensure the compounds we advance are bona fide gerotherapies. A gerotherapy means a drug that addresses an underlying core aging mechanism. Because aging is the #1 risk factor for most diseases, a gerotherapy-first approach ensures a pipeline in a pill - where each asset can be used in multiple clinical indications. Both aspects of the MOAT platform ensure we are focused on drug efficacy, which is a main reason therapies fail.
Lipids unite the Hallmarks of Cancer and Hallmarks of Aging
BIOIO-1xx1 and -2001 both act on lipid metabolism, which is increasingly appreciated for both longevity and oncology.